Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

12.54
+1.1810.39%
Post-market: 12.540.00000.00%16:10 EDT
Volume:703.44K
Turnover:8.65M
Market Cap:581.58M
PE:-2.48
High:12.74
Open:11.47
Low:11.35
Close:11.36
52wk High:40.43
52wk Low:9.10
Shares:46.38M
Float Shares:13.40M
Volume Ratio:1.17
T/O Rate:5.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0580
EPS(LYR):-18.5643
ROE:-111.55%
ROA:-67.11%
PB:1.67
PE(LYR):-0.68

Loading ...

Maplight Therapeutics - Phase 2 IRIS Trial Does Not Meet Primary Endpoint in Asd

THOMSON REUTERS
·
Jun 22

Maplight Therapeutics - to Engage With FDA in End-of-Phase 2 Meeting for Ml-004

THOMSON REUTERS
·
Jun 22

Maplight Announces Topline Results From Phase 2 IRIS Study for Ml-004 in Autism Spectrum Disorder

THOMSON REUTERS
·
Jun 22

Maplight Therapeutics Inc: Setia Is Not Entitled to Receive Any Severance Payment in Connection With His Separation

THOMSON REUTERS
·
Jun 19

Maplight Therapeutics - Jonathan Gillis to Continue as Principal Accounting Officer - SEC Filing

THOMSON REUTERS
·
Jun 19

Maplight Therapeutics - Vishwas Setia Separated as CFO Effective Immediately on June 18, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 19

MapLight Therapeutics names Jonathan Gillis interim CFO after Vishwas Setia exit

Reuters
·
Jun 19

MapLight Therapeutics Is Maintained at Buy by Stifel

Dow Jones
·
Jun 02

Maplight Therapeutics Inc : Stifel Raises Target Price to $36 From $28

THOMSON REUTERS
·
Jun 02

Assessing MapLight Therapeutics (MPLT) Valuation After Strong Recent Share Price Momentum

Simply Wall St.
·
Jun 01

MapLight Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
May 28

MapLight Therapeutics Initiated at Buy by UBS

Dow Jones
·
May 28

MapLight Therapeutics initiated with a Buy at UBS

TIPRANKS
·
May 27

Stock Track | MapLight Therapeutics Soars 5.11% Intraday on Craig-Hallum Buy Initiation with $43 Target

Stock Track
·
May 22

MapLight Therapeutics Initiated at Buy by Craig-Hallum

Dow Jones
·
May 22

Craig-Hallum bullish on MapLight Therapeutics, initiates with a Buy

TIPRANKS
·
May 21

Analyst Reiterates Buy on MapLight, Maintains $37 Price Target on Confidence in ML-007 and Pipeline Upside

TIPRANKS
·
May 20

Maplight CEO Christopher Kroeger sells $3.21 million common shares

Reuters
·
May 19

Buy Rating Reiterated on Clinical Catalysts and Strong Cash Runway; $37 Price Target Unchanged

TIPRANKS
·
May 15

MapLight Therapeutics Expands Pipeline Amid Rising Quarterly Losses

TIPRANKS
·
May 15